(SIX/SFZN) All closing conditions on the path toward Siegfried‘s acquisition of BASF’s pharmaceutical supply business have been fulfilled. They include regulatory assurance issued by Swissmedic that the necessary approval for the Evionnaz production site will be provided in time for the closing.
Siegfried assumes that the agreements between Siegfried and BASF (closing) and the connected transfer of the chemical-pharmaceutical production sites in France, Germany and Switzerland will be enforced as planned on September 30, 2015.
For further information:
Michael Hüsler, CFO
Tel. +41 (0)62 746 11 35
Mobile +41 (0)79 279 94 52
Siegfried Holding AG
Untere Brühlstrasse 4
Tel. +41 (0)62 746 11 11
Fax +41 (0)62 746 11 03
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, Germany, China, Malta and in the USA. At the end of 2014, Siegfried reported annual sales of CHF 315 million and employs at the time being approximately 1400 employees. Siegfried Holding AG is listed on the Swiss Exchange (SIX: SFZN).
Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediate steps and controlled substances, and provides development and production services for drugs in finished dosage forms including sterile filling.